Skip to main content
SynAct Pharma logo

SynAct Pharma — Investor Relations & Filings

Ticker · SYNACT ISIN · SE0008241491 LEI · 549300RRYIEFEQ72N546 ST Manufacturing
Open in API
Filings indexed 225 across all filing types
Latest filing 2026-05-27 Interim / Quarterly Rep…
Country SE Sweden
Listing ST SYNACT

About SynAct Pharma

https://synactpharma.com/en/

SynAct Pharma is a clinical-stage biotechnology company developing innovative medicines designed to resolve inflammation rather than solely inhibit it. The company's approach focuses on resolution therapy by leveraging melanocortin biology to restore immune balance. Its lead candidate, Resomelagon (AP1189), is a once-daily oral therapy that selectively activates melanocortin receptors on key immune cells. SynAct Pharma's development programs target a broad range of inflammatory conditions, including early intervention in chronic diseases to limit progression and the modulation of hyperinflammatory stages in acute viral diseases to reduce the risk of severe organ dysfunction.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2026
Interim / Quarterly Report Classification · 95% confidence The document is titled “Delårsrapport Januari – Mars 2026” and contains a full set of interim financial statements (income statement, balance sheet, cash flow, equity changes, notes), management commentary, Q&A with executives, operational highlights, and KPMG-style management assurance. It is a comprehensive quarterly report for the first quarter of 2026, not merely an announcement or summary. Under the definitions, this clearly qualifies as an Interim/Quarterly Report. Q1 2026
2026-05-27 Swedish
Interim / Quarterly Report 2026
Interim / Quarterly Report Classification · 95% confidence The document is titled “Interim Report January – March 2026” for SynAct Pharma AB, covering Q1 financial performance with actual income statement, balance sheet, cash flows, notes, CEO commentary, Q&A and other substantive financial data. It is a full interim/quarterly report rather than a brief announcement or transcript. Therefore it fits the definition of an Interim / Quarterly Report (Code: IR). Q1 2026
2026-05-27 English
Kallelse till årsstämma i SynAct Pharma AB
AGM Information Classification · 100% confidence The document is a detailed notice (kallelse) for the Annual General Meeting (AGM) of SynAct Pharma AB, scheduled for June 11, 2026. It includes the agenda items typical for an AGM such as election of chairman, approval of financial statements, discharge of board members, election of board and auditors, approval of remuneration report, and authorization for share issuance. It also provides procedural details for shareholders to participate, proxy instructions, and information on documents availability. The document is not the annual report itself but the official meeting notice and agenda for the AGM. Therefore, it fits the category of AGM Information (AGM-R). The document length and content confirm it is not a brief announcement or a regulatory filing but a full AGM notice.
2026-05-08 English
Notice of annual general meeting in SynAct Pharma AB
AGM Information Classification · 100% confidence The document is a notice of the annual general meeting (AGM) for SynAct Pharma AB, detailing the date, location, agenda items, procedures for participation, and proposals to be voted on at the meeting. It includes information about shareholder rights, proxy voting, board member elections, remuneration proposals, and authorization for share issues. The document is a formal invitation and agenda for the AGM rather than the actual minutes, presentations, or reports from the meeting. It is a typical AGM notice document intended to inform shareholders about the upcoming meeting and the matters to be discussed and decided upon. Therefore, it fits the category of AGM Information (AGM-R). The document length and detail confirm it is not a brief announcement but a full notice of the AGM.
2026-05-07 English
SynAct Pharmas valberedning inför årsstämman 2026
Board/Management Information Classification · 80% confidence The document is a press release announcing the composition changes of the nomination committee ahead of the company’s Annual General Meeting. This is an announcement concerning the company’s governance structure (the nomination committee), which falls under Board/Management Information: announcement of changes in board-related bodies or senior management. Therefore, it best fits MANG.
2026-04-23 Swedish
SynAct Pharma’s Nomination Committee ahead of the 2026 Annual General Meeting
Governance Information Classification · 70% confidence The document is a press release announcing the composition of the Nomination Committee for the upcoming Annual General Meeting. It concerns internal governance structure—specifically a committee of the board—rather than financial results, dividends, or a full report. It does not announce director or senior management appointments per se, but details governance arrangements under board structure. This aligns with the Governance Information category.
2026-04-23 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.